Related references
Note: Only part of the references are listed.Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma
Carlos H. Barrios et al.
CANCER (2012)
Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis
M. Pirani et al.
ANNALS OF ONCOLOGY (2011)
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis
Debra Josephs et al.
BJU INTERNATIONAL (2011)
Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy
Camillo Porta et al.
BMC CANCER (2011)
The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma
N. Shinohara et al.
BRITISH JOURNAL OF CANCER (2011)
Hypothyroidism in Patients With Renal Cell Carcinoma Blessing or Curse?
Manuela Schmidinger et al.
CANCER (2011)
Sunitinib in Metastatic Renal Cell Carcinoma: Recommendations for Management of Noncardiovascular Toxicities
Christian Kollmannsberger et al.
ONCOLOGIST (2011)
STrengthening the Reporting of OBservational studies in Epidemiology-Molecular Epidemiology (STROBE-ME): An Extension of the STROBE Statement
Valentina Gallo et al.
PLOS MEDICINE (2011)
Molecular Mechanisms of Cardiovascular Toxicity of Targeted Cancer Therapeutics
Hui Cheng et al.
CIRCULATION RESEARCH (2010)
Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels
Mariette H. W. Kappers et al.
HYPERTENSION (2010)
Overall Survival and Updated Results from a Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma
Yoshihiko Tomita et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2010)
Evaluation of the Value of Attribution in the Interpretation of Adverse Event Data: A North Central Cancer Treatment Group and American College of Surgeons Oncology Group Investigation
Shauna L. Hillman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Treatment of metastatic renal cell carcinoma
Maxine Sun et al.
NATURE REVIEWS UROLOGY (2010)
Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience
Jawaher Ansari et al.
ONCOLOGY REPORTS (2010)
Sunitinib Induces Hypothyroidism with a Markedly Reduced Vascularity
Noriko Makita et al.
THYROID (2010)
Impact of sample size on variation of adverse events and preventable adverse events: systematic review on epidemiology and contributing factors
Constanze Lessing et al.
QUALITY & SAFETY IN HEALTH CARE (2010)
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
David Moher et al.
INTERNATIONAL JOURNAL OF SURGERY (2010)
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis
G. Di Lorenzo et al.
ANNALS OF ONCOLOGY (2009)
Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers
Loukas F. Kontovinis et al.
BMC CANCER (2009)
Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
Martin E. Gore et al.
LANCET ONCOLOGY (2009)
Renal Cell Carcinoma: Diagnosis, Staging, and Surveillance
Chaan S. Ng et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2008)
The clinical implications of sunitinib-induced hypothyroidism:: a prospective evaluation
P. Wolter et al.
BRITISH JOURNAL OF CANCER (2008)
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Tammy F. Chu et al.
LANCET (2007)
A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake
Deborah Mannavola et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Thomas Force et al.
NATURE REVIEWS CANCER (2007)
Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity
Elaine Wong et al.
THYROID (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors
Jayesh Desai et al.
ANNALS OF INTERNAL MEDICINE (2006)
Review: A gentle introduction to imputation of missing values
A. Rogier T. Donders et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2006)
Meta-analysis of mortality and cancer incidence among workers in the synthetic rubber-producing industry
N. Alder et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2006)
Sunitinib in patients with metastatic renal cell carcinoma
Robert J. Motzer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Brief communication: Better ways to question patients about adverse medical events - A randomized, controlled trial
S Bent et al.
ANNALS OF INTERNAL MEDICINE (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
DF McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis
RC Flanigan et al.
JOURNAL OF UROLOGY (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Methodological index for non-randomized studies (MINORS):: Development and validation of a new instrument
K Slim et al.
ANZ JOURNAL OF SURGERY (2003)
Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists
RM Navari et al.
ANNALS OF PHARMACOTHERAPY (2003)
Can administrative data be used to compare postoperative complication rates across hospitals?
PS Romano et al.
MEDICAL CARE (2002)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
Share Paper
